Astria Therapeutics (ATXS) Q3 2025 earnings summary

Executive summary

• Entered into a license agreement with Kaken Pharmaceutical for navenibart in Japan, including $16M upfront, up to $16M in milestones, and tiered royalties up to 30%.

• BioCryst to acquire Astria in Q1 2026 for $8.55/share in cash plus 0.59 BioCryst shares per Astria share; transaction unanimously approved by both boards.

• Navenibart's Phase 3 ALPHA-ORBIT trial is progressing, with topline results expected in early 2027; first patient enrolled in the ORBIT-EXPANSE extension trial.

• Final Phase 1b/2 ALPHA-STAR results in 29 HAE patients show robust attack prevention and favorable safety profile for navenibart.

• STAR-0310, an OX40 antagonist, demonstrated best-in-class profile in initial Phase 1a data.

Financial highlights

• Astria receives a $16M upfront payment from Kaken, with additional $16M in potential commercialization and sales milestones.

• Tiered royalties on net sales in Japan range from mid-teens to 30%.

• Cash, cash equivalents, and short-term investments totaled $227.7M as of September 30, 2025, down from $344.3M a year prior.

• Net loss for Q3 2025 was $31.6M, compared to $24.5M in Q3 2024.

• Collaboration revenue was $0.7M for Q3 and YTD 2025, from the Kaken license agreement.

Outlook and guidance

• The agreement is expected to provide significant non-dilutive funding and extend cash runway into 2028.

• Astria anticipates Kaken's support will accelerate navenibart's development and regulatory approval in Japan.

• Topline results from the ALPHA-ORBIT Phase 3 trial anticipated in early 2027.

• Strategic alternatives being explored for STAR-0310 following positive Phase 1a results.